One Small Step For Pfizer & Moderna 'Vaccines'. One Effortless Giant Leap For Emerging SARS-CoV-2 Subvariants

The Omicron bivalent boosters were failing even as they bolted from the stable door unlocked by 8 mice, even against the Omicron Ba.1/Ba.2/Ba.4/Ba.5 subvariants they were supposed to protect against. Ba.1 and Ba.2 had virtually disappeared and the writing was already on the wall for Ba.4/5 with the emergence of BQ.1 and BQ1.1.

And here we are today, one month into a cold Northern Hemisphere winter in those countries which are highly jabbed and boosted, facing the meteoric rise of the new SC-2 vaccine escape subvariants on the block: BQ.1, BQ.1.1, XBB and XBB.1. If you got boosted with a bivalent mRNA ‘vaccine’ based on trials conducted on 8 ‘humanized’ mice, not only do you need your head examining, you completely and utterly wasted your time and have likely increased your risk of infection, probably done nothing to improve your resistance to serious disease or assorted serious adverse health events associated with the administration of the ‘vaccine’ itself.

Here are the highlights from a new study just published on BQ.1 and XBB, Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants:

The authors say:

The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly due to altered antibody evasion properties deriving from their additional spike mutations. Here, we report that neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by sera from vaccinees and infected persons was markedly impaired, including sera from individuals boosted with a WA1/BA.5 bivalent mRNA vaccine. Titers against BQ and XBB subvariants were lower by 13-81-fold and 66-155-fold, respectively, far beyond what had been observed to date. Monoclonal antibodies capable of neutralizing the original Omicron variant were largely inactive against these new subvariants, and the responsible individual spike mutations were identified. These subvariants were found to have similar ACE2-binding affinities as their predecessors. Together, our findings indicate that BQ and XBB subvariants present serious threats to current COVID-19 vaccines, render inactive all authorized antibodies, and may have gained dominance in the population because of their advantage in evading antibodies.

What this means is, at best, the current ‘vaccines’ and bivalent boosters are completely ineffective against the now dominant subvariants, BQ.1, BQ.1.1, XBB and XBB.1. Vanden Bossche warned them; using sub-optimal ‘leaky’ vaccines whilst the virus is still circulating merely generates immune pressure on the virus, causing it to adapt rapidly to escape the vaccinal antibodies. It’s now doing that, not gradually, but in huge leaps and bounds, accelerating away from the pitiful efforts of the vaccine manufacturers to control it, if indeed that is their intention, which I am dubious about. They are not going to keep up. This nimble GOF virus is going to outpace them every time and leave them in the dust.

I quote the study authors:

In one single leap, BQ.1.1 has changed as much from the outgoing dominant subvariant as that outgoing dominant variant has changed from D614G, way back in summer 2020, via several smaller mutations, giving rising to a number of successive circulating dominant variants and subvariants. But XBB is even worse: it’s way, way beyond the vaccine escape velocity; there must be something else other than conventional rocket fuel in the XBB tank. Pfizer and Moderna are going to get seriously burned if XBB takes off and starts causing disease. As Geert has warned us time and time again, it’s not a done deal that emerging variants will be milder and less virulent. Under the immune pressure exerted by the insane mass vaccination program, it’s possible that a highly infectious and more virulent variant or vaccine subvariant will emerge which is able to totally evade vaccinal antibodies.